Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.61 |
| ▸ | LMNA | P02545 | 7/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965535 | 0.96 | MAPT (0.57) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL3278531 | 0.86 | HTT (0.57) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL301695 | 0.85 | GAA (0.76) | MAPTLMNACACNA1HHTTGAA | |
| SCHEMBL1964073 | 0.82 | GAA (0.55) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL302890 | 0.81 | HTT (0.51) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL3235765 | 0.80 | CACNA1H (0.51) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL302889 | 0.79 | LMNA (0.54) | MAPTLMNACACNA1HHTTGAA | |
| SCHEMBL1965537 | 0.79 | MAPT (0.49) | MAPTLMNATP53THRBCACNA1H | |
| SCHEMBL8547733 | 0.78 | MAPT (0.71) | MAPTLMNATP53THRBHTT | |
| SCHEMBL3377228 | 0.77 | MAPT (0.74) | MAPTLMNAHTTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | claimed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | claimed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | claimed |
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | MAPT 3026/4885LMNA 1376/4885TP53 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.